Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion signals a strategic pivot for Datavault AI, which is known for its AI-driven data experiences and asset monetization in the Web 3.0 environment. By moving into healthcare, the company is positioning itself at the intersection of two high-growth sectors: digital health and blockchain-based data management. The global health and wellness market is projected to grow significantly, and patient-controlled data models are gaining traction as regulations like HIPAA and GDPR push for greater data portability and privacy.
For business leaders, the implications are twofold. First, the partnership creates a new revenue stream for Datavault AI through equity stakes and licensing fees, potentially boosting its financial performance. Second, it opens up a new market for DataMEDS, which can now offer its PharmacyChain technology to a broader range of healthcare providers, insurers and wellness companies. This could lead to more efficient data sharing, reduced administrative costs and new monetization opportunities for patient data.
Datavault AI’s technology suite, which includes acoustic sciences and data sciences divisions, is fully customizable and offers AI- and machine-learning-based automation. The company’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange enables digital twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata.
Investors should note that this agreement could enhance Datavault AI’s market position and create value for shareholders through the equity stake in DataMEDS. However, the success of the expanded licensing will depend on adoption by healthcare providers and patients. The full press release is available at this link.
Datavault AI is headquartered in Philadelphia, PA. For more information, visit the company’s website at https://dvlt.ai.
